Table 7.

Bioactivity and toxicity risks of synthesized (E)-2-(3-(substitutedstyryl)-5-(substitutedphenyl)-4,5-dihydropyrazol-1-yl)benzo[d]thiazole derivatives

Comp	GPCR ligand	Ion channel modulator	Kinase inhibitor	Nuclear receptor ligand	Protease inhibitor	Enzyme inhibitor	Mutagenic	Tumorigenic	Reproductive effective	Irritant
Z1	− 0.22	− 0.33	− 0.51	− 0.67	− 0.38	− 0.16	None	None	None	None
Z2	− 0.37	− 0.48	− 0.57	− 0.53	− 0.56	− 0.31	None	None	None	None
Z3	− 0.46	− 0.48	− 0.58	− 0.53	− 0.58	− 0.35	None	None	None	None
Z4	− 0.45	− 0.48	− 0.59	− 0.53	− 0.58	− 0.34	None	None	None	None
Z5	− 0.43	− 0.45	− 0.69	− 0.52	− 0.67	− 0.36	None	None	None	None
Z6	− 0.40	− 0.53	− 0.73	− 0.49	− 0.62	− 0.37	None	None	None	None
Z7	− 0.34	− 0.46	− 0.52	− 0.39	− 0.52	− 0.24	None	None	None	None
Z8	− 0.34	− 0.45	− 0.51	− 0.40	− 0.52	− 0.24	None	None	None	None
Z9	− 0.46	− 0.55	− 0.58	− 0.61	− 0.62	− 0.34	None	None	None	None
Z10	− 0.41	− 0.55	− 0.58	− 0.54	− 0.57	− 0.33	None	None	None	None
Z11	− 0.39	− 0.52	− 0.54	− 0.49	− 0.54	− 0.30	None	None	None	None
Z12	− 0.40	− 0.52	− 0.58	− 0.55	− 0.56	− 0.30	None	None	None	None
Z13	− 0.37	− 0.50	− 0.52	− 0.49	− 0.55	− 0.29	None	None	None	None
Z14	− 0.39	− 0.53	− 0.55	− 0.49	− 0.55	− 0.31	None	None	None	None
Z15	− 0.40	− 0.53	− 0.57	− 0.51	− 0.57	− 0.32	None	None	None	None
Z16	− 0.47	− 0.56	− 0.60	− 0.62	− 0.64	− 0.35	None	None	None	None
Z17	− 0.37	− 0.47	− 0.71	− 0.46	− 0.58	− 0.35	None	None	None	None
Z18	− 0.43	− 0.53	− 0.59	− 0.42	− 0.53	− 0.32	None	None	None	None
Z19	− 0.37	− 0.51	− 0.53	− 0.44	− 0.52	− 0.29	None	None	None	None
Z20	− 0.33	− 0.65	− 0.49	− 0.52	− 0.47	− 0.32	None	None	None	None

GPCR ligand: G-Protein coupled receptor ligand property